EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study ( TOG / GI ‐ SAFRADJU ‐2501)

Erman Akkus iD, Mehmet Kayaalp iD, Müzeyyen Aslı Ergözoğlu, Ilgın Koç Kuş, Doğan Bayram, Bilgeşah Kılıçtaş, Emel Ayvaz Güneyin, Ali Kalem iD, Haydar Temizyürek, Mehmet Mutlu Çatlı, Mehmet Sinan Akarca, Maral Martin Mıldanoğlu iD und 48 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70623 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Erman Akkus und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Türkiye. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recommended adjuvant chemotherapy (adj‐ChT) regimen for resected biliary tract cancers (BTC) is capecitabine (Cape); yet, the recommendation is based on limited evidence. Although varied adj‐ChTs have been employed in practice, robust real‐world data is scarce. We conducted a national, multicenter, hospital‐based registry study to evaluate adj‐ChTs in resected BTCs. Patients who received adj‐ChT (± radiotherapy) between 2010 and 2024 were included. Recurrence‐free (RFS) and overall survival (OS) were analyzed by adjusted Cox‐regression and propensity score‐based inverse‐probability‐of‐treatment‐weighting (IPTW), addressing selection bias. Among 617 patients from 44 centers, 513 were eligible. The most frequent adj‐ChTs were Cape (35.5% [ n = 182]), gemcitabine–cisplatin (Gem‐Cis; 22.4% [ n = 115]), gemcitabine–capecitabine (Gem‐Cape; 20.1% [ n = 103]), and gemcitabine (Gem; 10.7% [ n = 55]). Median RFS and OS with Cape were 19.7 (95% Confidence Interval [95% CI]: 14.2–41.1) and 41.9 months (95% CI: 25.9–69.2). In adjusted/controlled comparisons with Cape, no differences in RFS or OS were observed with Gem‐Cis (RFS: Hazard Ratio [HR] 1.13 [95% CI: 0.77–1.66]; OS: HR: 1.03 [95% CI: 0.66–1.61]), Gem‐Cape (RFS: HR 0.97 [95% CI: 0.68–1.38]; OS: HR: 0.81 [95% CI: 0.52–1.24]), or Gem (RFS: HR 1.00 [95% CI: 0.63–1.59]; OS: HR: 0.93 [95% CI: 0.55–1.57]). Similarly, IPTW analyses showed no difference in RFS and OS. Radiotherapy appeared to be associated with improved survival. Performance status, T‐stage, lymph‐node positivity, and R1‐resection were independently associated with RFS and OS. In conclusion, this real‐world study did not identify a regimen superior to Cape. Given the modest benefit of adj‐ChTs, novel approaches, including neoadjuvant and targeted/immunotherapy strategies, are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleChemotherapy, AdjuvantGemcitabineCapecitabineMaleAgedDeoxycytidineMiddle AgedCisplatinRegistries

Stichwörter der Autor:innen

adjuvant chemotherapybiliary tract cancercapecitabinecholangiocarcinomagallbladder cancer

Substanzen

GemcitabineCapecitabineDeoxycytidineCisplatin

Autor:innen und Institutionen

  • Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Türkiye.
  • Cancer Research Institute, Ankara University, Ankara, Türkiye.
  • Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Türkiye.
  • Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Türkiye.
  • Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Türkiye.
  • Department of Medical Oncology, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye.

ORCID-Profile: Erman Akkus, Mehmet Kayaalp, Ali Kalem, Maral Martin Mıldanoğlu, Elif Şahin, Elif Sertesen Çamöz

Zitieren

APA

Akkus, E., Kayaalp, M., Ergözoğlu, M. A., Koç Kuş, I., Bayram, D., Kılıçtaş, B., Ayvaz Güneyin, E., Kalem, A., Temizyürek, H., Çatlı, M. M., Akarca, M. S., Mıldanoğlu, M. M., Turhan, G., Kara, M., Arak, H., Arslan Tan, F., Paçacı, B., Yeşilyurt, B., Akdoğan, O., …, & Rimassa, L. (2026). Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study ( TOG / GI ‐ SAFRADJU ‐2501). International Journal of Cancer. https://doi.org/10.1002/ijc.70623

Vancouver

Akkus E, Kayaalp M, Ergözoğlu MA, Koç Kuş I, Bayram D, Kılıçtaş B, et al. Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study ( TOG / GI ‐ SAFRADJU ‐2501). International Journal of Cancer. 2026. doi:10.1002/ijc.70623

BibTeX
@article{Akkus2026,
  author = {Akkus, Erman and Kayaalp, Mehmet and Ergözoğlu, Müzeyyen Aslı and Koç Kuş, Ilgın and Bayram, Doğan and Kılıçtaş, Bilgeşah and Ayvaz Güneyin, Emel and Kalem, Ali and Temizyürek, Haydar and Çatlı, Mehmet Mutlu and Akarca, Mehmet Sinan and Mıldanoğlu, Maral Martin and Turhan, Görkem and Kara, Mahmut and Arak, Hacı and Arslan Tan, Feyza and Paçacı, Burak and Yeşilyurt, Berkay and Akdoğan, Orhun and Çetin, Emine Bihter and Çelik, Selahattin and Keskin Uzundere, Fatma and Şahin, Elif and Sadak Öcal, Zehra and Şeker Can, Lamia and Köylü, Bahadır and Fidan, Mehmet Cem and Kaplan Tüzün, Esmanur and Şakalar, Teoman and Sertesen Çamöz, Elif and Yüksel, Haydar Çağatay and Balçık, Onur Yazdan and Peker, Pınar and Yılmaz, Mehmet and Ala Enli, Şeymanur and Kölemen, Erdem and Oyucu Orhan, Sibel and Düzköprü, Yakup and Ersoy, Mustafa and Akın Telli, Tuğba and Yılmaz, Mesut and İlhan, Yusuf and Yıldırım, Atila and Coşar, Ramazan and Ürün, Müslih and Önder, Arif Hakan and Araz, Murat and Bayram, Ertuğrul and Yeşil Çınkır, Havva and Alkan, Ali and Gürbüz, Mustafa and Avcı, Nilüfer and Paksoy Türköz, Fatma and Kara, İsmail Oğuz and Köse, Fatih and Ünek, İlkay Tuğba and Bilici, Ahmet and Bal, Öznur and Yalçın, Şuayib and Rimassa, Lorenza},
  title = {Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study ( TOG / GI ‐ SAFRADJU ‐2501)},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70623}
}
Kostenlos starten →